Athersys Inc是一家生物技术公司。它致力于发现和开发候选治疗产品。它的MultiStem(invimestrocel)细胞疗法是一种异基因干细胞候选产品,是它的主要平台产品,目前处于临床开发的后期。多阶段细胞治疗包括重症监护适应症、神经系统疾病、炎症和免疫障碍、某些肺部疾病、心血管疾病和其他疾病的治疗。MultiStem细胞疗法是从成人骨髓中获得的人类干细胞制造的,这些细胞也可以从其他组织来源获得。它正在进行一项称为MASTERS-2的多阶段细胞疗法治疗缺血性中风的III期临床试验。它正在纳入一项关键的II/III期临床试验,评估多阶段细胞疗法对COVID-19诱导和其他病原体诱导的急性呼吸窘迫综合征(ARDS)患者的疗效。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Z. Kasey Rosado | Interim CFO & Director | 2024 | 52 |
| James G. Shook | Scientific and Clinical Advisor | 2000 | 86 |
| C. Thomas Caskey | Scientific and Clinical Advisor | 2000 | 86 |
| Catherine Verfaillie | Scientific and Clinical Advisor | - | - |
| Michael Simons | Scientific and Clinical Advisor | - | - |
| Ira Mellman | Scientific and Clinical Advisor | - | - |
| Gilbert Clincke | Scientific and Clinical Advisor | - | - |
| Brian H. Annex | Scientific and Clinical Advisor | - | - |
| F. Xavier Pi-Sunyer | Scientific and Clinical Advisor | - | - |
| John Wagner | Scientific & Clinical Advisor | - | - |
| Jerry Silver | Scientific and Clinical Advisor | - | - |
| Larry Wechsler | Scientific and Clinical Advisor | - | - |
| Warren Sherman | Scientific and Clinical Advisor | - | 75 |
| Marc Steven Penn | Scientific and Clinical Advisor | - | - |
| Richard T. Maziarz | Scientific & Clinical Advisor | - | - |
| Hillard M. Lazarus | Scientific & Clinical Advisor | - | - |
| Robert F. Kushner | Scientific and Clinical Advisor | - | - |
| David Hess | Scientific and Clinical Advisor | - | - |